Clinical Trials
23 trialsNCT07227402 2026-06-04
LITESPARK-033
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07405164 2026-05-29
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07489495 2026-05-29
LITESPARK-034
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07049926 2026-05-26
MK-3475-03C
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT04846920 2026-05-22
MK-6482-018
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT07023432 2026-05-22
Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07593040 2026-05-20
Moonlanding
Vall d'Hebron Institute of Oncology
Phase 2 Not yet recruiting
NCT04626479 2026-05-18
MK-3475-03A
Merck Sharp & Dohme LLC
Phase 1/2 Active not recruiting
NCT05239728 2026-05-15
MK-6482-022
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04195750 2026-05-14
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04626518 2026-05-06
KEYMAKER-U03
Merck Sharp & Dohme LLC
Phase 1/2 Active not recruiting
NCT04736706 2026-05-06
MK-6482-012
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04586231 2026-05-05
MK-6482-011
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT02861573 2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT05468697 2026-01-23
MK-6482-024
Merck Sharp & Dohme LLC
Phase 1/2 Active not recruiting
NCT06234605 2026-01-15
A Study of HC-7366 in Combination With Belzutifan (WELIREGâ„¢) in Patients With Renal Cell Carcinoma
HiberCell, Inc.
Phase 1 Recruiting
NCT07187778 2026-01-05
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05030506 2025-12-18
MK-6482-010
Merck Sharp & Dohme LLC
Phase 1 Active not recruiting
NCT05899049 2025-11-10
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT07179770 2025-09-23
Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)
NYU Langone Health
Phase 1 Recruiting
NCT07167329 2025-09-11
BELIEVE-VHL
AC Camargo Cancer Center
Phase 2 Recruiting
NCT04627064 2025-07-25
ABEMA Alone or in COMBO With MK-6482
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02974738 2025-07-10
MK-6482-001
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1 Active not recruiting